Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| Weiss Ratings | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | B- | |||
| Rating Factors | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.34 | |||
| Price History | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.45% | |||
| 30-Day Total Return | -4.42% | |||
| 60-Day Total Return | -3.58% | |||
| 90-Day Total Return | -13.40% | |||
| Year to Date Total Return | -4.06% | |||
| 1-Year Total Return | 33.67% | |||
| 2-Year Total Return | -21.31% | |||
| 3-Year Total Return | -63.96% | |||
| 5-Year Total Return | -12.31% | |||
| 52-Week High % Change | -26.93% | |||
| 52-Week Low % Change | 87.42% | |||
| Price | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.42 | |||
| 52-Week Low Price | $0.16 | |||
| 52-Week Low Price (Date) | Aug 15, 2024 | |||
| 52-Week High Price (Date) | Jan 13, 2025 | |||
| Valuation | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.30M | |||
| Enterprise Value | 8.16M | |||
| Price/Earnings (TTM) | 10.00 | |||
| Earnings Per Share (TTM) | 0.03 | |||
| Earnings Per Share Growth | -337.98% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.18 | |||
| Price/Book (Q) | 0.47 | |||
| Enterprise Value/Revenue (TTM) | 0.16 | |||
| Price | $0.31 | |||
| Enterprise Value/EBITDA (TTM) | 4.57 | |||
| Enterprise Value/EBIT | 5.63 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.30M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 973 926 0816 | |||
| Address | Building 15 Hillside, NJ 07205 | |||
| Website | ir.ibiopharma.com | |||
| Country | United States | |||
| Year Founded | 1980 | |||
| Profitability | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 2.77% | |||
| Profit Margin | 1.78% | |||
| Management Effectiveness | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.53% | |||
| Return on Equity | 4.85% | |||
| Income Statement | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 52.12M | |||
| Total Revenue (TTM) | 52.12M | |||
| Revenue Per Share | $1.67 | |||
| Gross Profit (TTM) | 5.07M | |||
| EBITDA (TTM) | 1.78M | |||
| EBIT (TTM) | 1.45M | |||
| Net Income (TTM) | 928.00K | |||
| Net Income Avl. to Common (TTM) | 928.00K | |||
| Total Revenue Growth (Q YOY) | 9.60% | |||
| Earnings Growth (Q YOY) | 130.37% | |||
| EPS Diluted (TTM) | 0.03 | |||
| EPS Diluted Growth (Q YOY) | 129.13% | |||
| Balance Sheet | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.46M | |||
| Cash Per Share (Q) | $0.08 | |||
| Total Current Assets (Q) | 18.15M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 19.73M | |||
| Current Ratio (Q) | 3.256 | |||
| Book Value Per Share (Q) | $0.65 | |||
| Total Assets (Q) | 25.66M | |||
| Total Current Liabilities (Q) | 5.58M | |||
| Total Debt (Q) | 1.32M | |||
| Total Liabilities (Q) | 5.93M | |||
| Total Common Equity (Q) | 19.73M | |||
| Cash Flow | INBP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -576.00K | |||
| Cash from Financing (TTM) | -10.00K | |||
| Net Change in Cash (TTM) | 1.73M | |||
| Levered Free Cash Flow (TTM) | 2.17M | |||
| Cash from Operations (TTM) | 2.32M | |||
